Stocktoria
Zymeworks Inc. ZYME
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-06-24
Zymeworks Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -87.3% | -179.7% | -181.6% | 31.6% | -808.2% |
| Net margin | -76.6% | -160.8% | -156.1% | 30.1% | -794.0% |
| FCF margin | -32.6% | -146.8% | -158.9% | 33.0% | -767.8% |
| Return on assets | -23.4% | -26.5% | -20.4% | 19.2% | -54.4% |
| Return on equity | -30.2% | -36.2% | -25.5% | 25.2% | -85.0% |
| Current ratio | 5.88 | 3.40 | 7.41 | 5.70 | 4.01 |
| Revenue growth | 38.9% | 0.4% | -81.6% | 1446.0% | — |
Source: SEC EDGAR filings · CIK 0001937653 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.